KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Shares Outstanding (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Shares Outstanding for 8 consecutive years, with $139.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.84% to $139.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.5 million through Dec 2025, up 1.84% year-over-year, with the annual reading at $139.5 million for FY2025, 1.84% up from the prior year.
  • Shares Outstanding hit $139.5 million in Q4 2025 for Vir Biotechnology, roughly flat from $139.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $139.5 million in Q4 2025 to a low of $129.9 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $134.6 million across 5 years, with a median of $134.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding: grew 19.88% in 2021 and later increased 1.11% in 2023.
  • Year by year, Shares Outstanding stood at $131.2 million in 2021, then rose by 1.58% to $133.2 million in 2022, then grew by 1.16% to $134.8 million in 2023, then rose by 1.62% to $137.0 million in 2024, then rose by 1.84% to $139.5 million in 2025.
  • Business Quant data shows Shares Outstanding for VIR at $139.5 million in Q4 2025, $139.0 million in Q3 2025, and $138.9 million in Q2 2025.